Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
DRAD's Cash to Debt is ranked higher than
92% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.27 vs. DRAD: No Debt )
DRAD' s 10-Year Cash to Debt Range
Min: 0.56   Max: No Debt
Current: No Debt

Equity to Asset 0.78
DRAD's Equity to Asset is ranked higher than
83% of the 453 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. DRAD: 0.78 )
DRAD' s 10-Year Equity to Asset Range
Min: -1.99   Max: 0.84
Current: 0.78

-1.99
0.84
Interest Coverage 11.40
DRAD's Interest Coverage is ranked higher than
51% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 241.11 vs. DRAD: 11.40 )
DRAD' s 10-Year Interest Coverage Range
Min: 0.66   Max: 9999.99
Current: 11.4

0.66
9999.99
F-Score: 7
Z-Score: 2.68
M-Score: -0.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 4.60
DRAD's Operating margin (%) is ranked higher than
72% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 5.49 vs. DRAD: 4.60 )
DRAD' s 10-Year Operating margin (%) Range
Min: -182.88   Max: 0.85
Current: 4.6

-182.88
0.85
Net-margin (%) 4.61
DRAD's Net-margin (%) is ranked higher than
74% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. DRAD: 4.61 )
DRAD' s 10-Year Net-margin (%) Range
Min: -190.47   Max: 0.87
Current: 4.61

-190.47
0.87
ROE (%) 7.58
DRAD's ROE (%) is ranked higher than
78% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.07 vs. DRAD: 7.58 )
DRAD' s 10-Year ROE (%) Range
Min: -14.95   Max: 1.24
Current: 7.58

-14.95
1.24
ROA (%) 6.02
DRAD's ROA (%) is ranked higher than
82% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. DRAD: 6.02 )
DRAD' s 10-Year ROA (%) Range
Min: -172.76   Max: 1.01
Current: 6.02

-172.76
1.01
ROC (Joel Greenblatt) (%) 32.28
DRAD's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 8.37 vs. DRAD: 32.28 )
DRAD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -134.97   Max: 3.47
Current: 32.28

-134.97
3.47
Revenue Growth (%) -4.80
DRAD's Revenue Growth (%) is ranked higher than
60% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. DRAD: -4.80 )
DRAD' s 10-Year Revenue Growth (%) Range
Min: -90.7   Max: 35.4
Current: -4.8

-90.7
35.4
» DRAD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

DRAD Guru Trades in Q4 2013

Jim Simons 835,400 sh (+10.09%)
» More
Q1 2014

DRAD Guru Trades in Q1 2014

Jim Simons 844,761 sh (+1.12%)
» More
Q2 2014

DRAD Guru Trades in Q2 2014

Jim Simons 889,030 sh (+5.24%)
» More
Q3 2014

DRAD Guru Trades in Q3 2014

Jim Simons 931,630 sh (+4.79%)
» More
» Details

Insider Trades

Latest Guru Trades with DRAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 31.20
DRAD's P/E(ttm) is ranked higher than
84% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 106.60 vs. DRAD: 31.20 )
DRAD' s 10-Year P/E(ttm) Range
Min: 15.36   Max: 202.11
Current: 31.2

15.36
202.11
P/B 2.10
DRAD's P/B is ranked higher than
81% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.78 vs. DRAD: 2.10 )
DRAD' s 10-Year P/B Range
Min: 0.19   Max: 3.12
Current: 2.1

0.19
3.12
P/S 1.30
DRAD's P/S is ranked higher than
85% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. DRAD: 1.30 )
DRAD' s 10-Year P/S Range
Min: 0.02   Max: 1.99
Current: 1.3

0.02
1.99
PFCF 24.70
DRAD's PFCF is ranked higher than
90% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. DRAD: 24.70 )
DRAD' s 10-Year PFCF Range
Min: 0.13   Max: 353
Current: 24.7

0.13
353
EV-to-EBIT 18.98
DRAD's EV-to-EBIT is ranked higher than
87% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 73.45 vs. DRAD: 18.98 )
DRAD' s 10-Year EV-to-EBIT Range
Min: -128.3   Max: 1991.6
Current: 18.98

-128.3
1991.6
Current Ratio 3.85
DRAD's Current Ratio is ranked higher than
80% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. DRAD: 3.85 )
DRAD' s 10-Year Current Ratio Range
Min: 1.03   Max: 5.53
Current: 3.85

1.03
5.53
Quick Ratio 3.44
DRAD's Quick Ratio is ranked higher than
81% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. DRAD: 3.44 )
DRAD' s 10-Year Quick Ratio Range
Min: 0.88   Max: 4.82
Current: 3.44

0.88
4.82

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.30
DRAD's Dividend Yield is ranked higher than
96% of the 185 Companies
in the Global Medical Devices industry.

( Industry Median: 1.37 vs. DRAD: 5.30 )
DRAD' s 10-Year Dividend Yield Range
Min: 1.3   Max: 5.33
Current: 5.3

1.3
5.33
Dividend Payout 1.54
DRAD's Dividend Payout is ranked higher than
80% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. DRAD: 1.54 )
DRAD' s 10-Year Dividend Payout Range
Min: 1   Max: 1.28
Current: 1.54

1
1.28
Yield on cost (5-Year) 5.30
DRAD's Yield on cost (5-Year) is ranked higher than
91% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 1.57 vs. DRAD: 5.30 )
DRAD' s 10-Year Yield on cost (5-Year) Range
Min: 1.3   Max: 5.33
Current: 5.3

1.3
5.33
Share Buyback Rate -0.70
DRAD's Share Buyback Rate is ranked higher than
81% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: -1.40 vs. DRAD: -0.70 )
DRAD' s 10-Year Share Buyback Rate Range
Min: 0.1   Max: -1314
Current: -0.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.60
DRAD's Price/Net Cash is ranked higher than
97% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. DRAD: 5.60 )
DRAD' s 10-Year Price/Net Cash Range
Min: 0.68   Max: 6
Current: 5.6

0.68
6
Price/Net Current Asset Value 3.60
DRAD's Price/Net Current Asset Value is ranked higher than
97% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. DRAD: 3.60 )
DRAD' s 10-Year Price/Net Current Asset Value Range
Min: 0.43   Max: 3.88
Current: 3.6

0.43
3.88
Price/Tangible Book 2.40
DRAD's Price/Tangible Book is ranked higher than
86% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.57 vs. DRAD: 2.40 )
DRAD' s 10-Year Price/Tangible Book Range
Min: 0.23   Max: 2.77
Current: 2.4

0.23
2.77
Price/DCF (Projected) 1.90
DRAD's Price/DCF (Projected) is ranked higher than
89% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. DRAD: 1.90 )
DRAD' s 10-Year Price/DCF (Projected) Range
Min: 1.1   Max: 2.93
Current: 1.9

1.1
2.93
Price/Median PS Value 1.60
DRAD's Price/Median PS Value is ranked higher than
62% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. DRAD: 1.60 )
DRAD' s 10-Year Price/Median PS Value Range
Min: 0.02   Max: 2.38
Current: 1.6

0.02
2.38
Price/Graham Number 1.70
DRAD's Price/Graham Number is ranked higher than
88% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. DRAD: 1.70 )
DRAD' s 10-Year Price/Graham Number Range
Min: 1.36   Max: 10.23
Current: 1.7

1.36
10.23
Earnings Yield (Greenblatt) 5.30
DRAD's Earnings Yield (Greenblatt) is ranked higher than
87% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. DRAD: 5.30 )
DRAD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 475
Current: 5.3

0.1
475
Forward Rate of Return (Yacktman) 0.76
DRAD's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 349 Companies
in the Global Medical Devices industry.

( Industry Median: 0.59 vs. DRAD: 0.76 )
DRAD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2491.2   Max: 590.8
Current: 0.76

-2491.2
590.8

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:FDV.Germany
Digirad Corp was incorporated in Delaware in 1997. The Company is a developer and manufacturer of medical diagnostic imaging systems including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications. The business is organized into two reportable segments: Digirad Imaging Solutions (DIS) and Diagnostic Imaging. It is a provider of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers through Digirad Imaging Solutions ("DIS") business segment. The Company sells medical diagnostic imaging systems including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications, as well as provides service on the products it sells through its Diagnostic Imaging segment. The target market for its products and services is comprised of cardiologists, internal medicine physicians, family practice physicians, and hospitals in the United States that perform or could perform nuclear and ultrasound diagnostic imaging procedures. The Company sells a line of nuclear imaging cameras for nuclear cardiology and general nuclear medicine applications. Its cameras are used in hospitals, imaging centers, physician offices and by mobile service providers. Its product Ergo large-field-of-view imaging system is targeted to hospitals with multi-camera general nuclear medicine departments, academic centers, pediatric hospitals, regional trauma centers, women's health centers, and cancer centers. Its Cardius XACT SPECT/CT system features a triple-head design and a low dose volume CT attenuation correction methodology, making it possible to perform studies faster with greater interpretation diagnostic confidence. It uses variety of materials, metals and mechanical and electrical components for production of its products. The Company maintain two sales organizations, which operate independently but in cooperation with each other: Diagnostic Imaging sales and DIS sales. The Company's operations comply with an array of federal and state laws and regulations.
» More Articles for DRAD

Headlines

Articles On GuruFocus.com
Top 3 Insider Buys Highlighted by Energy Companies Jul 12 2013 
DRAD Directors Increase Their Stake in the Medical Supply Company Apr 25 2013 
Expansion Initiates Insider Buying for NTS Apr 11 2013 
Digirad Corp. Reports Operating Results (10-K/A) Jul 30 2010 
Digirad Corp. Reports Operating Results (10-Q) Jul 29 2010 
Digirad Corp. Reports Operating Results (10-Q) Apr 29 2010 
Digirad Corporation Q3 2009 update Oct 29 2009 
Miguel Barbosa Interviews Famous Blogger, Greenbackd! Oct 29 2009 
Digirad Corp. Reports Operating Results (10-Q) Oct 22 2009 
Digirad Corporation Reports Fourth Quarter and Full Year 2008 Financial Results Feb 05 2009 

More From Other Websites
Nasdaq stocks posting largest volume increases Nov 25 2014
Digirad Corporation to Present at the LD Micro Conference on December 2 Nov 14 2014
Digirad Corporation to Present at the LD Micro Conference on December 2 Nov 14 2014
10-Q for Digirad Corp. Nov 03 2014
DIGIRAD CORP Files SEC form 10-Q, Quarterly Report Oct 31 2014
Digirad Corp Earnings Call scheduled for 11:00 am ET today Oct 31 2014
Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To... Oct 31 2014
Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To... Oct 31 2014
Digirad Corporation Reports Financial Results for Third Quarter and Nine Months of 2014 Oct 30 2014
DIGIRAD CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 30 2014
Digirad Corporation Reports Financial Results for Third Quarter and Nine Months of 2014 Oct 30 2014
Digirad Delivers Letter To PDI, Inc. Expressing Willingness To Acquire Company At A Premium To... Oct 29 2014
Digirad Delivers Letter To PDI, Inc. Expressing Willingness To Acquire Company At A Premium To... Oct 29 2014
Digirad Corporation to Release 2014 Third Quarter and Nine Month Financial Results on October 31,... Oct 15 2014
Digirad Corporation to Release 2014 Third Quarter and Nine Month Financial Results on October 31,... Oct 15 2014
DIGIRAD CORP Financials Aug 09 2014
DIGIRAD CORP Files SEC form 10-Q, Quarterly Report Aug 04 2014
DIGIRAD CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 01 2014
Lone Star reports 5.2% stake in Digirad Corp May 14 2014
DIGIRAD CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK